1Rutter A, Luger TA. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin. J Am Acad Dermatol,2001, 44: 1010-1024.
2Pyne D, Ehrenstein M, Morris V.The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases.Rheumatology (Oxford). 2002, 41: 367-374.
3Gelfand EW. Use of IGIV in the treatment of immune-mediated dermatologic disorders.J Investig Dermatol Symp Proc, 2004, 9:92-96.
4Akashi K, Nagasawa K, Mayumi T, et al.Successful treatment of refractory systemic lupus erythematosus with intravenous immunoglobulins. J Rheumatol, 1990, 17:375-379.
5Maier WP, Gordon DS, Howard RF, et al.Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia. Arthritis Rheum, 1990,33: 1233-1239.
6Cherin P, Piette JC, Wechsler B, et al. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol, 1994, 21: 1092-1097.
7Dalakas MC. High-dose intravenous immunoglobulin in inflammatory myopathies:experience based on controlled clinical trials. Neurol Sci, 2003, 24: S256-259.
8Jayne DR, Lockwood CM. Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol, 1996, 35:1150-1153.
9Jayne DR, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM, 2000, 93: 433-439.
10Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol, 2003, 139: 1051-1059.
